As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.
SINGAPORE, March 18, 2020 -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative.
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Is (ASLN) Outperforming Other Medical Stocks This Year?
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company, today announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, is scheduled to present an overview of the company on Wednesday, 26 February 2020 at 09:00am EST. An archived version of the presentation will be available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event.
ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares (“ADSs”) at a public offering price of $2.50 per ADS. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $12.8 million.
In the latest trading session, ASLAN Pharmaceuticals Ltd (ASLN) closed at $1.65, marking a +0.61% move from the previous day.
SINGAPORE, May 11, 2020 -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative.
ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.10, moving -1.87% from the previous trading session.
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SINGAPORE, Dec. 06, 2019 -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the.
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Is (ASLN) Outperforming Other Medical Stocks This Year?
The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Gilead (GILD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
ASLAN Pharmaceuticals Ltd. (ASLN) closed at $2.11 in the latest trading session, marking a -0.94% move from the prior day.
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not currently expect these measures to materially affect the projected timelines for the readout of interim, unblinded data later this year. ASLAN was recruiting patients into the second of three dose cohorts.